VERTEX PHARMACEUTICALS INC. financial statements, including revenue, expenses, profit, and loss
The total revenue of VX1 for the last quarter is 2.49 B EUR, and it's 9.06% higher compared to the previous quarter. The net income of Q1 24 is 1.02 B EUR.